Clinical Chemistry Analyzers Market by Product (Analyzers, Reagents, and Others), Test Type (Basic Metabolic Panels, Liver Panels, Renal Panels, Lipid Profiles, Thyroid Function Panels, Electrolyte Panels, and Specialty Chemical Tests), End-User (Hospitals & Clinics, Diagnostic Laboratories, Research Laboratories & Institutes, and Others): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026459 | Pages: 100 | Industry: Biotechnology | Date: Sep 2022 | Type: Global

The market crossed US$ 13.08 billion in 2022 and is expected to hit US$ 19.12 billion by 2030, recording a CAGR of 4.8% during the forecast period

 

Technologically advanced automated clinical chemistry analyzers are gaining popularity

The usage of clinical chemistry analyzers has increased rapidly over the past few decades, owing to significant advancements in technology and rising requirements of the healthcare industry. Clinical chemistry primarily analyzes internal bodily fluids and offers accurate diagnostic insights. Groundbreaking advances in technology, entry of innovative software, and improved production techniques are some of the factors that are projected to accelerate the growth of the market. For instance, Gold Standard Diagnostics ThunderBolt ELISA and CLIA Analyzer, a fully automated technology, are available cost-efficient and compact platforms. The flexible and friendly software is capable of programming a range of protocols. This ThunderBolt is available for both ELISA and Chemiluminescent (CLIA) applications.

Within the report, the market is segmented into product, test type, end-user, and geography. Based on product, the market is segmented into analyzers, reagents, and others. Based on test type, the market is segmented as basic metabolic panels, liver panels, renal panels, lipid profiles, thyroid function panels, electrolyte panels, and specialty chemical tests. Based on end-user, the market is segmented as hospitals & clinics, diagnostic laboratories, research laboratories & institutes, and others. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

The rising geriatric population and the increasing prevalence of chronic diseases are expected to fuel the market's growth

With advancing age, there has been a significant rise in the prevalence of cardiovascular, diabetes, hypertension, kidney diseases, and liver diseases. Increased cases of chronic illness are expected to generate substantial demand for tests prescribed for the diagnosis, prevention, and treatment of the same. According to the United States Census Bureau's Statistics, the total number of people aged 65 exceeded 50 million. From 2020 to 2030, the number of older people is expected to increase by 18 million. Although the number of people aged 85 years and older is expected to triple from an estimated 6 million, in the present scenario, to nearly 20 million by 2060. The rising geriatric population will lead to various diseases, resulting in high demand for clinical tests. Therefore, the clinical chemistry analyzers market is expected to witness high growth over the forecast period.

Automation in clinical chemistry is one of the major factors accelerating the market growth

Computer technology plays a crucial role in transforming the clinical chemistry segment, which, at present, is adopting informatics and automation. Automation in clinical chemistry has improved throughput to enable significantly higher testing volumes and efficiency and minimize human error. Moreover, automated clinical chemistry analyzers have proven their efficacy in reducing cross-contamination and offer a high degree of safety from biohazards. The demand for automated chemistry analyzers has thus witnessed substantial growth in recent years, and the trend is anticipated to continue during the forecast period.

Recent strategic developments in the clinical chemistry analyzers market

The clinical chemistry analyzers market has undergone several significant developments, and a few of these have been mentioned below:

·         In March 2021, Roche launched Cobas pure integrated solutions analyzer to help simplify operations in small to medium-sized labs. This new compact analyzer combines three technologies on a single platform, helping simplify daily lab operations with limited space and resources

·         In April 2022, Sysmex Europe launched its new three-part differential automated hematology analyzer XQ-320. XQ-320 brings excellence in quality to a diverse range of clinical laboratory environments with reliable technology and a new level of usability

·         In May 2022, Mindray Launched the Powerful yet Efficient BS-600M Chemistry Analyzer. The BS-600M is a powerful yet efficient chemistry analyzer designed to empower medium-volume laboratories with increased productivity, efficiency, and reliability

The clinical chemistry analyzers market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens AG, HORIBA Ltd., Sysmex Corporation, EKF Diagnostics, ELITech Group, Mindray Medical International Ltd. are among the prominent players operating in the market.

The target audience for the report:

  • Raw material providers
  • Government bodies, such as regulating authorities and policymakers
  • End users
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented based on:

  • Product:
    • Analyzers
    • Reagents
    • Other
  • Test Type:
    • Basic Metabolic Panels
    • Liver Panels
    • Renal Panels
    • Lipid Profiles
    • Thyroid Function Panels
    • Electrolyte Panels
    • Specialty Chemical Tests
  • End-User:
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Research Laboratories & Institutes
    • Other
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • South & Central America
    • Middle East & Africa
  • Companies Profiled
    • F. Hoffmann-La Roche Ltd.
    • Danaher Corporation
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Siemens AG
    • HORIBA Ltd.
    • Sysmex Corporation
    • EKF Diagnostics
    • ELITech Group
    • Mindray Medical International Ltd.

Companies profiled
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Siemens AG
- HORIBA Ltd.
- Sysmex Corporation
- EKF Diagnostics
- ELITech Group
- Mindray Medical International Ltd.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000